Ferric Citrate for hyperphosphatemia treatment in end stage renal disease patients, and the post-marketing clinical experience in Taiwan

李建德 醫師
高雄長庚紀念醫院

The safety and efficacy of Nephoxil® (Pharmaceutical grade of ferric citrate) have been demonstrated in previous studies for hyperphosphatemia treatment in end stage renal disease patients (ESRD). A Long-Term, Open-Label, Prospective Observational Phase IV Study was conducted in Taiwan to assess the long-term safety and effectiveness of Nephoxil® for the treatment of hyperphosphatemia in patients with ESRD undergoing dialysis in the real world situation. The study results showed that a treatment course of Nephoxil in a dosage modulation ranged from 1.5 g/day to 6.0 g/day well maintained the serum phosphorus of patients with ESRD under dialysis between 3.5 and 5.5 mg/dL. The long-term use of Nephoxil in ESRD patients for up to 12 months was safe and well tolerated. Monitoring of iron index revealed a mild incremental increase in serum ferritin level. Dose requirement of erythropoietin in treating anemia was also reduced. Overall, the safety and efficacy results of this study were similar to those of reported in other previous studies. Treatment-related adverse events of Nephoxil in the target population remain predictable and well manageable by the healthcare professionals. The study results showed a favorable benefit to risk ratio on Nephoxil for treating hyperphosphatemia in patients with ESRD on dialysis.